Sana biotechnology to present preclinical data on its engineered hypoimmune allogeneic car t cells at the 2022 american association for cancer research annual meeting

Seattle, march 08, 2022 (globe newswire) -- sana biotechnology, inc. (nasdaq: sana), a company focused on creating and delivering engineered cells as medicines, today announced that preclinical data from its hypoimmune t cell program will be presented at the 2022 american association for cancer research (aacr) annual meeting taking place april 8-13, 2022 in new orleans, la.
SANA Ratings Summary
SANA Quant Ranking